This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > ERC1671 (Gliovac) for recurrent grade IV glioma

< Back

ERC1671 (Gliovac) for recurrent grade IV glioma


Cancer and Palliative Care

March 2019

ERC1671 is in development for the treatment of high grade, recurrent gliomas. Gliomas are the most common type of primary brain tumour. They develop from the glial cells that support the nerve cells of the brain and spinal cord. Glioblastoma multiforme (GBM) is the most common and most malignant of all high grade gliomas. Gliosarcoma is a rare, malignant and fast-growing type of glioma, all classified as high grade tumours. High grade gliomas are very difficult tumours to treat due to the problems in completely removing the tumour and their resistance to radiotherapy and chemotherapy.
ERC1671 is composed of whole tumour cells and cell fragments taken from the patient and three other donors with the same type of cancer. By receiving tumour cells from different people, the patient’s immune system is exposed to several different tumour-associated antigens (TAA), or proteins, minimizing the chance that tumour cells might escape from the body’s defences. It also is believed this approach will trigger a stronger immune response against the TAA on the patient’s tumour. This strategy in combination with the immune response inherent in the patient’s own cells may lead to the elimination of glioblastoma cells and offer an additional treatment option for high grade glioma patients who currently have few effective therapies available.

Innovation Observatory Voice 1

I am aware of two cases of terminal glioma who had the treatment abroad. They have been well 8 months after the treatment with ERC1671 with excellent quality of life. I think ERC1671 is a treatment which potentially can keep the glioma under control. In the era when everyone is working on the bench to develop tumor specific vaccines, ERC1671 is ready for use at bedside. I hope that NICE will seriously consider it and support it appropriately .

Dr Elene Psiachou-Leonard - Posted ago

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts